prod:prod_dcx-login
Anne Beaubrun
Vice President, Value and Access
Dr. Anne Beaubrun is a senior leader with extensive experience and multiple successes in the biopharmaceutical and diagnostic arena. Anne is currently the Vice President of Value & Access at Cepheid, leading the organization’s health economics and outcomes research (HEOR), global market access strategy, and regional market access engagement functions. Our department’s mission is to drive patient access through establishing value for patients, customers, payers, governments and healthcare systems.
Previous to the role, Anne was the VP of HEOR at Cepheid, pioneering the Integrated Evidence Planning process to ensure cross-functional alignment of evidence and building a robust evidence generation engine supporting the company’s position as a global scientific leader in molecular diagnostics. Prior to Cepheid, Anne was the Head of Global HEOR at Global Blood Therapeutics [now Pfizer post 2022 acquisition] where she built a team of HEOR professionals based in the US, Europe, and the Middle East to successfully launch therapeutics for patients with sickle cell disease. Earlier roles include the Global Head of HEOR at Portola Pharmaceuticals [now an AstraZeneca company] and roles with increasing responsibility at Gilead Sciences and Amgen, Inc. in both the epidemiology and health economics departments.
During her career, Anne has authored over 85 congress presentations and peer reviewed publications. Anne earned a B.A. in Public Policy Studies from Duke University and a Ph.D. from the University of North Carolina at Chapel Hill with a focus in pharmacoeconomics & pharmacoepidemiology.